Code: 6472, Market: TPEx Listed Company
Bora Pharmaceuticals Co., Ltd. was established in 2007 and has grown to become a leading CDMO (contract development and manufacturing organization) company in Taiwan. Major milestones include: - 2009: Restructured and renamed as Bora International Co. with Mr. Sheng Pao-Shi as chairman. - 2013: Acquired Tainan Gongtian facility from Eisai Taiwan, allowing Bora to undertake CDMO contracts and expand exports. Renamed as Bora Pharmaceuticals. - 2014: Acquired Union Chemical for its drug permits, sales channels and reputation. Listed on TPEx Emerging Stock Board. - 2017: Listed on Taipei Exchange. Established Yuta Heath joint venture. - 2018: Acquired Bora Pharmaceutical Laboratories facility and signed supply agreement with US Amneal. - 2019: Established US and Canadian subsidiaries. - 2020: Acquired GSK Canada facility assets and signed 5-year supply agreement. - 2021: New headquarters in Neihu Ruiguang Building. Formed partnership with Taishin Healthcare. - 2022: New R&D center approved for Hsinchu Science Park. Acquired Eden Biologics operating assets for large molecule CDMO. Acquired TWi Pharmaceuticals for R&D and manufacturing. First Taiwan eye drop plant approved by USFDA. Through mergers, acquisitions and partnerships over the past 10+ years, Bora Pharma has rapidly expanded its manufacturing capabilities, R&D, sales channels and scale to become the largest pharmaceutical company in Taiwan by production capacity. Bora provides small and large molecule CDMO services to global clients.